HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Personal Folders Download to citation manager Author home page(s): David G. Affleck Nader Moazami Jennifer R. Smith Permission Requests Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by De Wet, C. J. Articles by Smith, J. R. Search for Related Content PubMed PubMed Citation Articles by De Wet, C. J. Articles by Smith, J. R. Related Collections Transplantation - heart

J Thorac Cardiovasc Surg 2004;127:1058-1067
© 2004 The American Association for Thoracic Surgery

Cardiopulmonary support and physiology

Inhaled prostacyclin is safe, effective, and affordable in patients with pulmonary hypertension, right heart dysfunction, and refractory hypoxemia after cardiothoracic surgery

^a Department of Anesthesiology, Washington University School of Medicine and Barnes Jewish Hospital, St Louis, Mo, USA,
^b Division of Cardiothoracic Surgery, Washington University School of Medicine and Barnes Jewish Hospital, St Louis, Mo, USA
^c Department of Pharmacy, Barnes Jewish Hospital, St Louis, Mo, USA

Presented at the Society of Cardiovascular Anesthesiology Meeting, Miami, Fla, May 2003, and the Twenty-ninth Annual Meeting of The Western Thoracic Surgical Association, Carlsbad, Calif, June 18-21, 2003.

Received for publication June 17, 2003; revisions received September 11, 2003; revisions received November 5, 2003; accepted for publication December 1, 2003.

^* Address for reprints: Eric Jacobsohn, MBChB, MHPE, FRCPC, Washington University School of Medicine, Department of Anesthesiology, 660 Euclid Ave, Campus Box 8054, St Louis, MO 63110, USA
jacobsoe{at}msnotes.wustl.edu

BACKGROUND: The purpose of this study was to describe our institutional experience in using inhaled prostacyclin as a selective pulmonary vasodilator in patients with pulmonary hypertension, refractory hypoxemia, and right heart dysfunction after cardiothoracic surgery.

METHODS: Between February 2001 and March 2003, cardiothoracic surgical patients with pulmonary hypertension (mean pulmonary artery pressure >30 mm Hg or systolic pulmonary artery pressure >40 mm Hg), hypoxemia (PaO₂/fraction of inspired oxygen <150 mm Hg), or right heart dysfunction (central venous pressure >16 mm Hg and cardiac index <2.2 L · min^–1 · m^–2) were prospectively administered inhaled prostacyclin at an initial concentration of 20,000 ng/mL and then weaned per protocol. Hemodynamic variables were measured before the initiation of inhaled prostacyclin, 30 to 60 minutes after initiation, and again 4 to 6 hours later.

RESULTS: One hundred twenty-six patients were enrolled during the study period. At both time points, inhaled prostacyclin significantly decreased the mean pulmonary artery pressure without altering the mean arterial pressure. The average length of time on inhaled prostacyclin was 45.6 hours. There were no adverse events attributable to inhaled prostacyclin. The average cost for inhaled prostacyclin was $150 per day. Compared with nitric oxide, which costs $3000 per day, the potential cost savings over this period were $681,686.

CONCLUSIONS: Inhaled prostacyclin seems to be a safe and effective pulmonary vasodilator for cardiothoracic surgical patients with pulmonary hypertension, refractory hypoxemia, or right heart dysfunction. Overall, inhaled prostacyclin significantly decreases mean pulmonary artery pressures without altering the mean arterial pressure. Compared with nitric oxide, there is no special equipment required for administration or toxicity monitoring, and the cost savings are substantial.

This article has been cited by other articles:

				K. Subramaniam and J.-P. Yared Management of Pulmonary Hypertension in the Operating Room Seminars in Cardiothoracic and Vascular Anesthesia, June 1, 2007; 11(2): 119 - 136. [Abstract] [PDF]

				Y. Lamarche, L. P. Perrault, S. Maltais, K. Tetreault, J. Lambert, and A. Y. Denault Preliminary experience with inhaled milrinone in cardiac surgery Eur. J. Cardiothorac. Surg., June 1, 2007; 31(6): 1081 - 1087. [Abstract] [Full Text] [PDF]

				A. Y. Denault, Y. Lamarche, P. Couture, F. Haddad, J. Lambert, J.-C. Tardif, and L. P. Perrault Inhaled milrinone: a new alternative in cardiac surgery? Seminars in Cardiothoracic and Vascular Anesthesia, December 1, 2006; 10(4): 346 - 360. [Abstract] [PDF]

				M. Winterhalter, S. Fischer, R. Tessmann, A. Goerler, S. Piepenbrock, A. Haverich, and M. Strueber Using inhaled iloprost to wean from cardiopulmonary bypass after implanting a left ventricular assist device. Anesth. Analg., August 1, 2006; 103(2): 515 - 516. [Full Text] [PDF]

				S. Muzaffar, N. Shukla, G. D. Angelini, and J. Y. Jeremy Inhaled prostacyclin is safe, effective, and affordable in patients with pulmonary hypertension, right-heart dysfunction, and refractory hypoxemia after cardiothoracic surgery J. Thorac. Cardiovasc. Surg., December 1, 2004; 128(6): 949 - 950. [Full Text] [PDF]